---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-001579"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2024-01-18T23:59:59+00:00"
generated_at: "2026-06-06T21:51:25.985560+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Talphera sells DSUVIA/DZUVEO royalty rights to XOMA for $8M upfront

## Summary
- Sold rights to royalty and milestone payments from Vertical Pharma to XOMA for $8M cash.
- Potential milestones up to $116.5M based on net sales; Talphera retains partial rights after stepdown.
- Stepdown occurs when XOMA receives a minimum payment amount; specific amount not disclosed.
- After stepdown: Talphera keeps 50% of DoD sales royalties and milestones; XOMA gets 100% non-DoD.
- Agreement includes customary reps, warranties, and indemnification obligations.

## SEC filing metadata
- accession: 0001437749-24-001579
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2024-01-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774924001579/0001437749-24-001579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774924001579/acrx20240117_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-001579
- JSON: https://secwatch.observer/filing/0001437749-24-001579.json
- Plain text: https://secwatch.observer/filing/0001437749-24-001579.txt

## Key facts
- Material Agreements
  TALPHERA, INC. entered into Payment Interest Purchase Agreement with XOMA (US) LLC valued at $8 million (effective 2024-01-12).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: XOMA (US) LLC
  - Value: $8 million
  - Effective: 2024-01-12
  source text: On January 12, 2024, Talphera, Inc. (the “Company”) and XOMA (US) LLC (“XOMA”) entered into a Payment Interest Purchase Agreement (the “Purchase Agreement”) for the sale by the Company to XOMA, in exchange for $8 million, of the Company’s right, title and interest in and to certain amounts payable to the Company (collectively, the “Purchased Receivables”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427925/000143774924001579/0001437749-24-001579-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.